Table 2.
Major trials for DOACs in AF
| DOAC | Trial | CrCl included (mL/min) | Efficacy | Safety |
|---|---|---|---|---|
| Dabigatran | RE‐LY | At least 30 | Dabigatran noninferior to warfarin | Similar overall hemorrhage, increased gastrointestinal and life threatening hemorrhage with 150 mg BID dosing |
| Rivaroxaban | ROCKET‐AF | At least 30 | Rivaroxaban noninferior to warfarin | No difference in major bleeding |
| Apixaban | ARISTOTLE | At least 25 | Apixaban superior to warfarin | Lower bleeding overall |
| Edoxaban | ENGAGE | At least 30 | Edoxaban noninferior to warfarin | Lower bleeding overall |
Abbreviations: AF, atrial fibrillation; CrCl, creatinine clearance; DOAC, direct oral anticoagulant.